Do you consider FOLFIRINOX dose adjustments for elderly patients with a good performance status in the neoadjuvant setting for resectable pancreatic adenocarcinoma?

This is a question worth revisiting in light of recent data.

The question assumes that we would prefer to use FOFLIRINOX as peri-operative treatment in resectable PDA and this is commonly the case based on extrapolation from cross-trial comparisons of randomized data evaluating combination therapy i...

I never use full dose Folfirinox. I have for many years used reduced doses in the neoadjuvant setting, seeing no reason why it should not be better to give when patients tolerate drugs, and from other studies, it has been superior to gemcitabine. Multiple studies have shown modified doses are just a...

Unfortunately, the patients we see in community practice are often 15-20 years older than ones studied in clinical trials. Most geriatric lectures or articles that I have read comment on the biologic difference between younger and older patients. More specifically, less muscle, more fat, decreased r...